EnWave Corp (NWVCF)

[Dromers]

EnWave Signs Material Transfer Agreement with AstraZeneca to Trial Radiant Energy Vacuum Technology for Pharmaceutical Dehydration
GlobeNewswireJul 9, 2021 9:00 AM EDT
VANCOUVER, British Columbia, July 09, 2021 (GLOBE NEWSWIRE) -- EnWave Corporation (TSX-V:ENW | FSE:E4U) (“EnWave”, or the “Company”) announces that it has signed a material transfer agreement (“MTA”) with MedImmune Limited, an affiliate of AstraZeneca AB (LSE/STO/Nasdaq: AZN) (“AZ”), to facilitate the trialing of EnWave’s Radiant Energy Vacuum (“REV”) technology for the dehydration of liquid monoclonal antibody formulations. AZ will send proprietary materials to EnWave’s testing facility in Vancouver, Canada to conduct initial proof-of-concept trials. If successful, the two companies intend to negotiate a more robust agreement to allow for further research and development activities.